Glucocorticoid receptor and vascular endothelial growth factor in nephrotic syndrome

Acta Paediatrica, International Journal of Paediatrics

Volumn 95, Issue 5, 2006, Pages 587-593

  Wasilewska, Anna ^a   Zoch Zwierz, Walentyna ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

Glucocorticosteroids; Nephrotic syndrome; Vascular endothelial growth factor

Indexed keywords

GLUCOCORTICOID RECEPTOR; PREDNISONE; VASCULOTROPIN;

ADOLESCENT; ARTICLE; CHILD; CONTROLLED STUDY; CORRELATION ANALYSIS; DOSE RESPONSE; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMAN; LYMPHOCYTE; MAJOR CLINICAL STUDY; MALE; NEPHROTIC SYNDROME; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN URINE LEVEL; RELAPSE; TREATMENT OUTCOME;

ADOLESCENT; ANTIGENS, CD3; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GLUCOCORTICOIDS; HUMANS; LYMPHOCYTE COUNT; MALE; NEPHROTIC SYNDROME; PREDNISONE; RECEPTORS, GLUCOCORTICOID; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 33646912792     PISSN: 08035253     EISSN: 16512227     Source Type: Journal    
DOI: 10.1080/08035250500459725     Document Type: Article

References (33)

1. Brenchley PE. VEGF/VPF: a modulator of microvascular function with potential roles in glomerular pathophysiology. J Nephrol 1996;9:10-7.
2. Kondo S, Yoshizawa N, Kusumi Y, Takeuchi A, Torikata C. Studies of glomerular permeability factor (GPF) in focal glomerular sclerosis and the relationship between GPF and vascular permeability factor (VPF). Clin Nephrol 1999;52:278-84.
3. Brenchley PE. Vascular permeability factors in steroid-sensitive nephrotic syndrome and focal segmental glomerulosclerosis. Nephrol Dial Transplant 2003;18:21-5.
4. Horita Y, Miyazaki M, Koji T, Kobayashi N, Shibuya M, Razzaque MS, et al. Expression of vascular endothelial growth factor and its receptors in rats with protein-overload nephrosis. Nephrol Dial Transplant 1998;13:2519-28.
5. Cheong HI, Lee JH, Hahn H, Park HW, Ha IS, Choi Y. Circulating VEGF and TGF-beta1 in children with idiopathic nephrotic syndrome. J Nephrol 2001;14:263-9.
6. Bailey E, Bottomley MJ, Westwell S, Pringle JH, Furness PN, Feehally J, et al. Vascular endothelial growth factor mRNA expression in minimal change, membranous, and diabetic nephropathy demonstrated by non-isotopic in situ hybridisation. J Clin Pathol 1999;52:735-8.
7. Ferrara N. Role of vascular endothelial growth factor in the regulation of angiogenesis. Kidney Int 1999;56:794-814.
8. Schrijvers BF, Flyvbjerg A, de Vriese AS. The role of vascular endothelial growth factor (VEGF) in renal pathology. Kidney Int 2004;65:2003-17.
9. Datta K, Li J, Karumanchi SA, Wang E, Rondeau E, Mukhopadhyay D. Regulation of vascular permeability factor/vascular endothelial growth factor (VPF/VEGF-A) expression in podocytes. Kidney Int 2004;66:1471-8.
10. Brown LF, Berse B, Tognazzi K. Vascular permeability factor mRNA and protein expression in human kidney. Kidney Int 1992;42:1457-61.
11. Simon M, Rockl W, Hornig C. Receptors of vascular endothelial growth factor/vascular permeability factor (VEGF/VPF) in fetal and adult human kidney: Localization and (1251)VEGF binding sites. J Am Soc Nephrol 1998;9:1032-44.
12. Thomas S, Vanuystel J, Gruden G, et al. Vascular endothelial growth factor receptors in human mesangium in vitro and in glomerular disease. J Am Soc Nephrol 2000;11:1236-43.
13. Remuzzi G, Benigni A. Repairing renal lesions: Will VEGF be the builder? Kidney Int 2000;58:2594-5.
14. Webb NJ, Watson CJ, Roberts IS, Bottomley MJ, Jones CA, Lewis MA, et al. Circulating vascular endothelial growth factor is not increased during relapses of steroid-sensitive nephrotic syndrome. Kidney Int 1999;55:1063-71.
15. Boner G, Cox AJ, Kelly DJ, Tonar A, Bernheim J, Langham RG, et al. Does vascular endothelial factor (VEGF) play a role in the pathogenesis of minimal change disease? Nephrol Dial Transplant 2003;18:2293-9.
16. Honkanen EO, Teppo AM, Gronhagen-Riska C. Decreased urinary excretion of vascular endothelial growth factor in idiopathic membranous glomerulonephritis. Kidney Int 2000;57:2343-9.
17. Matsumoto K, Kanmatsuse K. Elevated vascular endothelial growth factor levels in the urine of patients with minimal-change nephrotic syndrome. Clin Nephrol 2001;55:269-74.
18. Kitamoto Y, Tokunaga H, Miyamoto K, Tomita K. VEGF is an essential molecule for glomerular endothelial cells and its excretion in urine might be a unique marker of glomerular injury. Rhinso Byori 2000;48:485-90.
19. Glassock RJ. Circulating permeability factors in the nephrotic syndrome: A fresh look at an old problem. J Am Soc Nephrol 2003;14:541-3.
20. Ha IS, Um EY, Jung HR, Park HW, Cheong HI, Choi Y. Glucocorticoid diminishes vascular endothelial growth factor and exacerbates proteinuria in rats with mesangial proliferative glomerulonephritis. Am J Kidney Dis 2002;39:1001-10.
21. Wasilewska A, Zoch-Zwierz W, Tomaszewska B, Wierciński R, Stasiak-Barmuta A. Expression of glucocorticoid receptors in mononuclear cells in nephrotic syndrome. Pediatr Nephrol 2003;18:778-82.
22. Berki T, Kumanovics G, Kumanowics A, Falus A, Ujhelyi E, Nemeth P. Production and flow cytometric application of a monoclonal anti-glucocorticoid receptor antibody. J Immunol Methods 1998;214:19-27.
23. Nitta K, Uchida K, Kimata N, Honda K, Horita S, Hayashi T, et al. Increased serum levels of vascular endothelial growth factor in human crescentic glomerulonephritis. Clin Nephrol 1999;52:76-82.
24. Navarro C, Candia-Zuniga L, Silveira LH, Ruiz V, Gaxiola M, Avila MC, et al. Vascular endothelial growth factor plasma levels in patients with systemic lupus erythematosus and primary antiphospholipid syndrome. Lupus 2002;11:21-4.
25. Matsumoto K, Kanmatsuse K. Transforming growth factor-beta 1 inhibits vascular permeability factor release by T cells in normal subjects and in patients with minimal-change nephrotic syndrome. Nephron 2001;87:111-7.
26. Matsumoto K, Ohi H, Kanmatsuse K. Effects of interleukin-15 on vascular permeability factor release by peripheral blood mononuclear cells in normal subjects and in patients with minimal-change nephrotic syndrome. Nephron 1999;82:32-8.
27. Eremina V, Sood M, Haigh J, Nagy A, Lajoie G, Ferrara N, et al. Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases. J Clin Invest 2003;111:707-16.
28. Vogelmann SU, Nelson WJ, Myers BD, Lemley KV. Urinary excretion of viable podocytes in health and renal disease. Am J Physiol Renal Physiol 2003;285:F40-8.
29. Kaven C, Spraul CW, Zavazava N, Lang GK, Lang GE. Thalidomide and prednisolone inhibit growth factor-induced human retinal pigment epithelium cell proliferation in vitro. Ophthalmologica 2001;215:284-9.
30. Nauck M, Karakiulakis G, Perruchoud AP, Papakonstantinou E, Roth M. Corticosteroids inhibit the expression of the vascular endothelial growth factor gene in human vascular smooth muscle cells. Eur J Pharmacol 1998;341:309-15.
31. Asai K, Kanazawa H, Kamoi H, Shiraishi S, Hirata K, Yoshikawa J. Increased levels of vascular endothelial growth factor in induced sputum in asthmatic patients. Clin Exp Allergy 2003;33:595-9.
32. Heiss JD, Papavassiliou E, Merrill MJ, Nieman L, Knightly JJ, Walbridge S, et al. Mechanism of dexamethasone suppression of brain tumor-associated vascular permeability in rats. Involvement of the glucocorticoid receptor and vascular permeability factor. J Clin Invest 1996;98:1400-8.
33. Aida K, Shi Q, Wang J, VandeBerg JL, McDonald T, Nathanielsz P, et al. The effects of betamethasone (BM) on endothelial nitric oxide synthase (eNOS) expression in adult baboon femoral arterial endothelial cells. J Steroid Biochem Mol Biol 2004;91:219-24.